引用次数
引用: 10,515
H-指数: 55
I10-指数 : 224
出版物: 807
Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia
J. Harenberg , C. Giese , R. Zimmermann
Atherosclerosis 74 ( 3) 247 -249
111
1988
Urokinase-Behandlung der Phlegmasia coerulea dolens*
R. Zimmermann , H. Mörl , J. Harenberg
Deutsche Medizinische Wochenschrift 104 ( 44) 1563 -1567
5
1979
Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes.
J. Harenberg
Journal of Thrombosis and Haemostasis 2 ( 4) 547 -550
84
2004
Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers
U. Hoffmann , J. Harenberg , K. Bauer , G. Huhle
Blood Coagulation & Fibrinolysis 13 ( 4) 289 -296
11
2002
Tissue factor pathway inhibitor: proposed heparin recognition region.
J. Harenberg , R. Malsch , D. L. Heene
Blood Coagulation & Fibrinolysis 6
15
1995
Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers
J. Harenberg , M. Jeschek , M. Acker , R. Malsch
Blood Coagulation & Fibrinolysis 7 ( 1) 49 -56
14
1996
Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
J. Harenberg , Th. Reichel , R. Malsch , J. Hirsh
Blood Coagulation & Fibrinolysis 7 ( 4) 453 -458
13
1996
Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
J. Harenberg , R. Malsch , M. Angelescu , C. Lange
Blood Coagulation & Fibrinolysis 7 ( 4) 477 -483
15
1996
Thrombolytische Therapie der tiefen Beinvenenthrombose mit Urokinase
R. Zimmermann , J. Harenberg , H. Mörl , H. M. Kuhn
Journal of Molecular Medicine 60 ( 10) 489 -496
9
1982
Thrombin—antithrombin III complexes
J. Harenberg
ECAT Assay Procedures A Manual of Laboratory Techniques 117 -123
1
1992
Ximelagatran zur Therapie thromboembolischer Erkrankungen
T. Fenyvesi , I. Jörg , J. Harenberg
Hamostaseologie 22 ( 3) 107 -111
1
2002
Fibrinbildung und Fibrinolyse Biochemie, Physiologie und Molekularbiologie
M. Barthels , J. Harenberg , I. Pabinger , K.T. Preissner
Hamostaseologie 24 ( 2) 5 -7
2004
Langzeitantikoagulation bei Patienten mit Leberzirrhose und Implantation eines transjugulären, intrahepatischen portosystemischen Shunts
G. Huhle , S. Lessmann , U. Hoffmann , Th. Filser
Hamostaseologie 20 ( 02) 107 -109
2000
Wirkung von Thrombininhibitoren auf ein humanes, experimentelles Thrombosemodell zur Vermeidung von Tierversuchen
K. Zokai , L. Piazolo , T. Fenyvesy , U. Hoffmann
Hamostaseologie 20 ( 4) 201 -204
2000
Ist eine Adjustierung an das Körpergewicht für niedermolekulares Heparin zur Therapie der TVT erforderlich
H. K. Breddin , C. M. Kirchmaier , J. Harenberg
Hamostaseologie 21 ( 3) 143 -145
2001
Lack of effect of cimetidine on action of phenprocoumon.
J. Harenberg , R. Zimmermann , Ch. Staiger , J. X. de Vries
European Journal of Clinical Pharmacology 23 ( 4) 365 -367
15
1982
Heparin-induced thrombocytopenia: pathophysiology and new treatment options.
J. Harenberg , I. Jörg , T. Fenyvesi
Pathophysiology of Haemostasis and Thrombosis 32 289 -294
17
2002
OC-10 Anticoagulant effects after termination of therapy using once weekly subcutaneous injections of idraparinux in patients with acute venous thromboembolism
J. Harenberg , C.H. Weiss , I. Joerg , T. Fenyvesi
Thrombosis Research 120
2007
LMWH - new mechanisms of action.
J. Harenberg
Thrombosis Research 123 ( 3)
4
2009
C0303: Prospective Controlled Study to Identify the Preference of Patients for a Conventional Or Direct Oral Anticoagulant Using a Short Questionnaire
S. Zolfaghari , J. Harenberg , L. Frölich , P. Wild
Thrombosis Research 133
2014